Patents by Inventor Roberto Justo De Antueno
Roberto Justo De Antueno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192783Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: ApplicationFiled: September 19, 2022Publication date: June 22, 2023Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
-
Patent number: 11459362Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: GrantFiled: January 11, 2019Date of Patent: October 4, 2022Assignee: ENTOS PHARMACEUTICALS INC.Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
-
Publication number: 20190367566Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: ApplicationFiled: January 11, 2019Publication date: December 5, 2019Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
-
Patent number: 10227386Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: GrantFiled: September 29, 2011Date of Patent: March 12, 2019Assignee: Entos Pharmaceuticals Inc.Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
-
Publication number: 20140314831Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: ApplicationFiled: September 29, 2011Publication date: October 23, 2014Applicant: Innovascreen Inc.Inventors: Roy Duncan, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt, Eileen Kathryn Clancy
-
Publication number: 20090060900Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.Type: ApplicationFiled: June 11, 2007Publication date: March 5, 2009Applicant: Xenon Genetics Inc.Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka
-
Publication number: 20080220500Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.Type: ApplicationFiled: August 20, 2007Publication date: September 11, 2008Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka, Y. Paul Goldberg
-
Patent number: 7297523Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.Type: GrantFiled: November 29, 2001Date of Patent: November 20, 2007Assignee: Xenon Pharmaceuticals Inc.Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka, Y. Paul Goldberg
-
Patent number: 7256028Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.Type: GrantFiled: October 26, 2001Date of Patent: August 14, 2007Assignee: Xenon Genetics Inc.Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka
-
Publication number: 20040146872Abstract: The present invention relates to methods for identifying genes regulated by fat and their subsequent use in determining compositions for use in the treatment of disease, by utilizing the identified genes and their proteins. The identified compositions regulate the expression of the fat regulated genes or modulate the activity of their protein products. The nucleotide and amino acid sequences for METP, a novel mitochondrial carrier protein and FTF1, a fat responsive transcription factor, are taught. The nucleotide sequence for A1BG, a plasma glycoprotein is taught. The nucleotide and amino add sequences for human GPAT and rat GLOL are taught. Control sequences for human METP, GLOL, FTF1, SCD, GPAT and A1BG are taught.Type: ApplicationFiled: November 28, 2003Publication date: July 29, 2004Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka, Y. Paul Goldberg
-
Publication number: 20040096435Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.Type: ApplicationFiled: November 24, 2003Publication date: May 20, 2004Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D Kenneth Jenkins, Solomon O Nwaka
-
Publication number: 20040086899Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.Type: ApplicationFiled: November 20, 2003Publication date: May 6, 2004Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D Kenneth Jenkins, Solomon O Nwaka, Y Paul Goldberg
-
Publication number: 20040053234Abstract: The present invention relates to polynucleotides that control desaturase genes and to drug screening assays for identifying pharmaceutially active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy, by utilizing fatty acid desaturase enzymes and the genes which encode them as targets for intervention. The drug screening method identifies nucleotides, proteins, compounds and/or other pharmacological agents, which effectively modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes.Type: ApplicationFiled: March 24, 2003Publication date: March 18, 2004Inventors: Michael David Winther, Heidi Lynn Smith-King, Andre Ponton, Roberto Justo De Antueno, Stephen John Allen